Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Menley & James

This article was originally published in The Tan Sheet

Executive Summary

Menley & James: Sales down slightly to $4 mil. from $4.1 mil. for the fourth quarter (ended Dec. 31); sales for the year were up slightly to $14.4 mil. from $14.3 mil. in 1996. Net income fell, with the company recording a $91,000 loss for the quarter and a $247,000 loss for the year compared to a $83,000 profit for the fourth quarter of 1996 and a $38,000 loss last year. Despite increasing competition from Rx-to-OTC switch and private label products, the company says it maintained sales by focusing on "selected unique products" and through marketing agreements for Medeva's Humibid Plus expectorant/decongestant, Rystan's Derifil internal deodorant and Ferndale's capsaicin topical analgesic (a private label version of Genderm's Zostrix)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel